Collegium to Present Highlights From Xtampza(TM) ER (Oxycodone Extended-Release Capsules) Clinical Development Program at PAINWeek
The five posters include results from a series of studies that evaluate the abuse-deterrent properties of Xtampza ER, conducted in accordance with guidance on abuse-deterrent opioids from the
"These data further support the development of new abuse-deterrent technologies that may help people suffering with chronic pain to receive effective treatment, while potentially reducing the risk of misuse and abuse," said
The posters to be presented at the Scientific Session reception on
-
Abuse-Deterrent Properties of Oxycodone DETERx, an Extended-release Formulation for Chronic Pain Management - In Vitro Studies Characterizing Oxycodone DETERx: An Abuse-deterrent, Extended-release Formulation
- Oral and Intranasal Human Abuse Potential of Oxycodone DETERx: An Abuse-deterrent, Extended-release Formulation
-
Sprinkle Administration of Oxycodone DETERx : An Abuse-deterrent, Extended-release Formulation - Evaluation of the Durability of Pain Relief of Oxycodone DETERx: An Extended-release, Abuse-deterrent Formulation throughout its 12-hour Dosing Interval
About Xtampza ER
Collegium's lead product candidate, Xtampza™ ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza ER using its proprietary DETERx® technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
About
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. The new drug application, or NDA, submission for Xtampza ER, the Company's lead product candidate, was accepted for review by the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that we will obtain approval for Xtampza ER or any of our other product candidates from the
CONTACT:Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com